Alto Neuroscience ($ANRO) Insider Trading & Smart Money Activity
Alto Neuroscience, Inc. ($ANRO) has 2 insider trades and 2 13F position changes on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($3.57M), net -$3.57M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$3.57M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 2
- Analyst ratings on file
- 0
ANRO insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 2 |
| Q3 2026 | 0 | 2 · $3.57M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All ANRO insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Smith Nicholas ConradPRESIDENT AND CFO | Sell (Open-market sale) 10b5-1 | 24.06K sh | $621.10K | — | ||||||
| Insider | Smith Nicholas ConradPRESIDENT AND CFO | Sell (Open-market sale) 10b5-1 | 110.83K sh | $2.95M | — | ||||||
| 13F | Alkeon Capital Management | Reduced | -250K sh | $4.88M | — | ||||||
| 13F | Alkeon Capital Management | Reduced | -250K sh | $6.19M | — |
1W / 1M / 6M = how ANRO moved from the trade or filing date.
Insider trading in ANRO: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Smith Nicholas Conrad | PRESIDENT AND CFO | 2 | -$3.57M | Sep 30, 2026 |
Institutions moving ANRO (13F)
Frequently asked questions
Are ANRO insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 2 open-market sales worth $3.57M, a net -$3.57M.
What is the latest insider trade in ANRO?
Smith Nicholas Conrad, PRESIDENT AND CFO filed a sell (open-market sale) of 24.06K sh worth $621.10K on Sep 30, 2026.
Which institutions changed their ANRO positions?
Recent 13F filers moving the stock include Alkeon Capital Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.